<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="brief-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Trop. Dis</journal-id>
<journal-title>Frontiers in Tropical Diseases</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Trop. Dis</abbrev-journal-title>
<issn pub-type="epub">2673-7515</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fitd.2022.1085401</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Tropical Diseases</subject>
<subj-group>
<subject>Perspective</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Contact screening and management in a high-transmission MDR-TB setting in Papua New Guinea: Progress, challenges and future directions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Majumdar</surname>
<given-names>Suman S.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/564936"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Islam</surname>
<given-names>Shahidul</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>G. Khai Lin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/725689"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Morris</surname>
<given-names>Lucy</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bauri</surname>
<given-names>Mathias</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Geoff</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kama</surname>
<given-names>Gabriel</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Keam</surname>
<given-names>Tess</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peacock-Smith</surname>
<given-names>Abby</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Finch</surname>
<given-names>Stacia</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marukutira</surname>
<given-names>Tafireyi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2078120"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhatt</surname>
<given-names>Shivani</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drewett</surname>
<given-names>George</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1225329"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wratten</surname>
<given-names>Melanie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murray</surname>
<given-names>Alexa</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pank</surname>
<given-names>Naomi</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Masah</surname>
<given-names>Christopher</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bala</surname>
<given-names>Ruth</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Umali</surname>
<given-names>Scott</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2102494"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kalon</surname>
<given-names>Stobdan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2129620"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greig</surname>
<given-names>Jane</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chani</surname>
<given-names>Kudakwashe</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2101241"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kal</surname>
<given-names>Margaret</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graham</surname>
<given-names>Stephen Michael</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>TB Elimination &amp; Implementation Science, Burnet Institute</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Paediatrics, University of Melbourne</institution>, <addr-line>Melbourne, VIC</addr-line>, <country>Australia</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>RID-TB Project Burnet Institute</institution>, <addr-line>Daru</addr-line>, <country>Papua New Guinea</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>PNG Country Program, Burnet Institute</institution>, <addr-line>Port Moresby</addr-line>, <country>Papua New Guinea</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>Public Health Services, Western Provincial Health Authority</institution>, <addr-line>Daru</addr-line>, <country>Papua New Guinea</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>National TB Program, National Department of Health</institution>, <addr-line>Port Moresby</addr-line>, <country>Papua New Guinea</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Amyn Abdul Malik, Yale University, United States</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Jennifer Furin, Harvard University, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Suman S. Majumdar, <email xlink:href="mailto:suman.majumdar@burnet.edu.au">suman.majumdar@burnet.edu.au</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Major Tropical Diseases, a section of the journal Frontiers in Tropical Diseases</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>01</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>3</volume>
<elocation-id>1085401</elocation-id>
<history>
<date date-type="received">
<day>31</day>
<month>10</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>12</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Majumdar, Islam, Huang, Morris, Bauri, Chan, Kama, Keam, Peacock-Smith, Finch, Marukutira, Bhatt, Drewett, Wratten, Murray, Pank, Masah, Bala, Umali, Kalon, Greig, Chani, Kal and Graham</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Majumdar, Islam, Huang, Morris, Bauri, Chan, Kama, Keam, Peacock-Smith, Finch, Marukutira, Bhatt, Drewett, Wratten, Murray, Pank, Masah, Bala, Umali, Kalon, Greig, Chani, Kal and Graham</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Daru, South Fly District, Papua New Guinea is a high transmission setting for multidrug-resistant tuberculosis (MDR-TB). An emergency response by the Government in 2014 established a high-quality model for treatment and care. Household contact screening and management commenced in 2016 with TB preventive treatment (TPT) for well young child (&lt;5 years) contacts of people with drug-susceptible TB and later expanded to young child contacts of MDR-TB. The model of care is community-based and led by non-specialist health workers, under supervision. An electronic medical record system supports care, reporting and operational research. Community engagement and education has been central, with a concerted focus on peer-led counselling and patient-centred services to improve TPT uptake and completion. Challenges include the application of households as the unit of intervention for detection of active TB and TPT provision. Our implementation experience in Daru has highlighted significant population mixing dynamics with most transmission likely occurring outside the household. We propose a community-wide screening approach with the provision of TPT based on testing to include older children, adolescents, and young adults. As there is the possibility of MDR-TB infection irrespective of the drug susceptibility of the household index case, a novel option is a combination TPT regimen of 6 months of daily isoniazid and levofloxacin (6HLfx). A sensitive aged-related algorithm to detect and exclude active TB is being developed. Ongoing community engagement, quality data systems with operational research to evaluate approaches are critical in high transmission MDR-TB settings.</p>
</abstract>
<kwd-group>
<kwd>tuberculosis</kwd>
<kwd>contact management</kwd>
<kwd>multidrug-resistant TB (MDR-TB)</kwd>
<kwd>Papua New Guinea</kwd>
<kwd>contact screening</kwd>
<kwd>implementation research</kwd>
</kwd-group>
<contract-num rid="cn001">PGS 1191614</contract-num>
<contract-num rid="cn002">NHMRC Woolcock Scholarship 2020</contract-num>
<contract-num rid="cn003">RID-TB Project , STRATUM Project , CURB-TB Project (1201008)</contract-num>
<contract-sponsor id="cn001">National Health and Medical Research Council<named-content content-type="fundref-id">10.13039/501100000925</named-content>
</contract-sponsor>
<contract-sponsor id="cn002">Royal Australasian College of Physicians<named-content content-type="fundref-id">10.13039/501100001232</named-content>
</contract-sponsor>
<contract-sponsor id="cn003">Australian Government<named-content content-type="fundref-id">10.13039/100015539</named-content>
</contract-sponsor>
<counts>
<fig-count count="1"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="42"/>
<page-count count="8"/>
<word-count count="4076"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Tuberculosis (TB) is the leading infectious cause of morbidity and mortality in Papua New Guinea (PNG) (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The emergence and increasing transmission of multidrug-resistant TB (MDR-TB) is a major challenge (<xref ref-type="bibr" rid="B3">3</xref>). On Daru Island in the South Fly District of Western Province, PNG, there is an unprecedented MDR-TB outbreak with a TB notification rate of 2,021 per 100,000 for all TB and 594 per 100,000 for MDR/RR-TB (rifampicin-resistant) in 2015 (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In 2014, the PNG National Department of Health and Western Provincial Health Authority (WPHA) initiated an emergency response to MDR-TB, which has resulted in the stabilisation of TB notifications, improved treatment outcomes and a reduction in TB-related mortality (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). A description of the geographical, social and demographic context in Daru, which is located in the transboundary region between PNG and the Australian Torres Strait, has been detailed elsewhere (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>).</p>
<p>A comprehensive community-based model of care for TB was established through the introduction of evidence-based practice, with significantly improved outcomes and introduction of novel tools including bedaquiline-containing treatment regimens (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>). Community engagement and patient-centred support services have been central to delivery of care (<xref ref-type="bibr" rid="B11">11</xref>). An electronic patient-level medical record system (EMRS - Bahmni, Thoughtworks) was implemented in 2016 to support quality patient care, program monitoring and operational research (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B9">9</xref>). The screening and management of household contacts of people with TB commenced in 2016. TB preventive treatment (TPT) for well young child (&lt;5 years) contacts of drug-susceptible (DS) TB index cases was introduced in 2017 and extended to those of MDR-TB index cases in 2019 (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>In Daru, as in many other high-transmission and resource-limited settings, best practice strategies and tools for TB and MDR-TB are often under-utilised or not prioritised (<xref ref-type="bibr" rid="B13">13</xref>). Active case finding through contact screening and TPT for eligible at-risk contacts is a programmatic priority. However, application to high transmission MDR-TB settings presents additional challenges that require specific considerations and novel approaches. <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref> summarises the current approach, challenges and solutions for contact screening and management in Daru, PNG.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Contact screening and management &#x2013; current approach, challenges and solutions in Daru, PNG 2017 - 2022.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Program Area</th>
<th valign="top" align="center">Approach to date</th>
<th valign="top" align="center">Challenges and considerations</th>
<th valign="top" align="center">Solutions and future directions</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left" style="background-color:#aeaaaa"><bold>Model of contact screening and management</bold>
</td>
<td valign="top" align="left">&#x2022; Community-based (decentralised clinics)<break/>&#x2022; Non-specialist public health team<break/>&#x2022; Health promoters and education<break/>&#x2022; Integrated screening for malnutrition and treatment for helminths in children &lt;5<break/>&#x2022; Standard monthly follow up, including education and counselling if required</td>
<td valign="top" align="left">&#x2022; Human resource shortage<break/>&#x2022; Operational interruptions to CXR, laboratory and internet<break/>&#x2022; COVID-19 impacts led to suspension of contact investigation<break/>&#x2022; Large multigenerational households and contact networks (kinship, visitors) &#x2013; definition of household</td>
<td valign="top" align="left">&#x2022; Community-wide screening: detect, treat, prevent approach with evaluation<break/>&#x2022; Task-shifting to nurses and community health workers<break/>&#x2022; Technical partner implementation support<break/>&#x2022; Households as unit of intervention</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#aeaaaa"><bold>Detecting active TB</bold>
</td>
<td valign="top" align="left">&#x2022; Referral to hospital, dedicated TB diagnostic service<break/>&#x2022; Gastric aspirate, lymph node aspirates and stool samples performed for mWRD e.g. Xpert Ultra<break/>&#x2022; Chest radiography (CXR)</td>
<td valign="top" align="left">&#x2022; Excluding active TB in children and adolescents<break/>&#x2022; Optimal use of CXR &#x2013; as abnormalities require follow-up</td>
<td valign="top" align="left">&#x2022; Excluding active TB in children and adolescents with sputum for mWRD and CXR<break/>&#x2022; Optimal use of CXR, consider in all &gt;10 or &gt;15<break/>&#x2022; Computer-aided detection of CXR &gt;15</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#aeaaaa"><bold>TB Preventive Treatment (TPT)</bold>
</td>
<td valign="top" align="left">&#x2022; TPT to child contacts &lt;5 (and people living with HIV)<break/>&#x2022; Shorter TPT regimens: 3RH<break/>&#x2022; 6Lfx if evidence of infection (TST positive)</td>
<td valign="top" align="left">&#x2022; Household exposure may not correlate with resistance of infecting strain as transmission occurring outside the household and multiple index cases<break/>&#x2022; Who to test for TB infection<break/>&#x2022; Optimal TPT for a high MDR-TB setting<break/>&#x2022; Fluoroquinolone resistant exposure</td>
<td valign="top" align="left">&#x2022; TPT for TST positive in 5-34 years<break/>&#x2022; TPT for &lt;5 years according to household exposure<break/>&#x2022; Novel combination regimen with 6HLfx<break/>&#x2022; Individualised approach to fluroquinolone resistant exposure</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#aeaaaa"><bold>Community education &amp; patient education and support</bold>
</td>
<td valign="top" align="left">&#x2022; Community education and health promotion campaign to explain &#x201c;sleeping TB&#x201d; (TB infection) prior to TPT service initiation<break/>&#x2022; Peer counselling model. With family based care<break/>&#x2022; Visual tools and aides (education games)<break/>&#x2022; Child-friendly space in TPT clinic</td>
<td valign="top" align="left">&#x2022; TPT for the well<break/>&#x2022; Structural barriers &#x2013; poverty, low health literacy, overcrowding, food insecurity,<break/>&#x2022; Stigma and trust<break/>&#x2022; Mobile population</td>
<td valign="top" align="left">&#x2022; Community advisory group to co-design public health activities and education materials<break/>&#x2022; Engagement of priority populations<break/>&#x2022; Continue peer-led model<break/>&#x2022; Person-centred care</td>
</tr>
<tr>
<td valign="top" align="left" style="background-color:#aeaaaa"><bold>Program monitoring and data systems</bold>
</td>
<td valign="top" align="left">&#x2022; Paper-based household mapping tools for contact investigation<break/>&#x2022; Electronic medical record system for data entry, management, reporting and analysis<break/>&#x2022;Cascade of care indicator set (individual or longitudinal)</td>
<td valign="top" align="left">&#x2022; Comprehensive guidance on tools, definitions and processes for contact screening and management not available<break/>&#x2022; Resources required to support EMRS<break/>&#x2022; The need for re-identification across multiple health interactions for care (no ID system)</td>
<td valign="top" align="left">&#x2022; Continue EMRS and cascade reporting<break/>&#x2022; Unique identifiers: health book with ID and verbal ID. Biometrics not feasible.<break/>&#x2022; Cascades of care for quality improvement</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>mWRD, molecular WHO-recommended rapid diagnostics; DS, drug-susceptible; MDR/R,  multidrug-resistant/rifampicin-resistant; RH, rifampicin and isoniazid; Lfx-levofloxacin; TST, tuberculin skin test; CXR, chest radiography; CAD, computer-aided detection; TPTTB, preventive treatment; EMRS, electronic medical record system; ID'identification.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s2">
<title>Current approach to household contact screening and management</title>
<p>In Daru, a dedicated public health TB Team consisting of a health extension officer (an auxiliary medical officer), nursing officers, community health workers and health promoters conduct contact screening for all newly detected bacteriologically confirmed pulmonary or extrapulmonary TB under the supervision of a medical officer. Following verbal consent by index cases or their guardian and the household head, contact screening occurs at the household level. Education is provided by trained health promoters to household contacts, who are defined as any person who lives in the same house as the index case within three months prior to diagnosis, including spending time during the day. Contacts with a positive symptom screen are referred to the TB diagnostic clinic for investigation and asymptomatic young child contacts to the TPT clinic. Young children are also screened for malnutrition which is managed according to local guidance and includes empiric treatment for soil transmitted helminths. Screening and management are provided by non-specialist nursing community health worker teams, in a community-based model of care (decentralised clinics) following standard operating procedures.</p>
<sec id="s2_1">
<title>Detecting active TB in contacts</title>
<p>TB detection with treatment of disease is a critical role of contact screening and management along with determining eligibility for TPT. In Daru, there is a TB diagnostic clinic in the hospital where contacts with TB-related symptoms are referred for further investigation including chest radiography (CXR) and appropriate specimens such as sputum or lymph node aspirate for Xpert Ultra as per PNG and World Health Organisation guidelines (<xref ref-type="bibr" rid="B14">14</xref>). If RR-TB is detected, a specimen is sent to the national laboratory for culture and drug-susceptibility testing and molecular assays for early diagnosis of fluoroquinolone-resistance. Gastric aspirate and/or stool samples for Xpert Ultra are taken from symptomatic child contacts unable to expectorate sputum. Asymptomatic contacts are not routinely referred for investigation, including asymptomatic young child contacts who are eligible for TPT.</p>
</sec>
<sec id="s2_2">
<title>TB preventive treatment</title>
<p>The provision of TPT to eligible household contacts is widely recommended but implementation in resource-constrained settings remains limited (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B15">15</xref>). TPT should be routinely offered to well young child (&lt;5 years) household contacts of people with confirmed or presumptive pulmonary DS-TB (<xref ref-type="bibr" rid="B16">16</xref>). The protective efficacy of TPT is well established (<xref ref-type="bibr" rid="B17">17</xref>) and the recently recommended shorter regimens are associated with high rates of completion and very few adverse events (<xref ref-type="bibr" rid="B16">16</xref>). The program in Daru was the first in PNG to systematically introduce a community-based model of TPT in 2016 using 6 months of daily isoniazid (6H) for young child contacts. A TPT regimen of 3 months of daily rifampicin and isoniazid (3RH) &#x2013; recommended by WHO in 2018 &#x2013; has been associated with high uptake, completion and safety in young child contacts under programmatic conditions in resource-limited settings (<xref ref-type="bibr" rid="B18">18</xref>). The availability in PNG of dispersible, child-friendly combined formulations for active TB since 2016 (<xref ref-type="bibr" rid="B19">19</xref>), led to the successful implementation of 3RH for young child contacts of DS-TB in Daru from 2019.</p>
<p>In Daru, up to 20% of incident TB is MDR/RR-TB (<xref ref-type="bibr" rid="B5">5</xref>). TPT as 3RH or 6H may not be protective for child contacts of MDR-TB and is not recommended in that context (<xref ref-type="bibr" rid="B16">16</xref>). Furthermore, known exposure to DS-TB does not necessarily determine that infection is limited to a drug-susceptible strain only (<xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>). The optimal TPT regimen following infection with MDR-TB is unknown. A regimen that includes daily levofloxacin for at least six months (6Lfx) is widely used. Observational evidence from a number of settings suggests that a fluoroquinolone-based TPT regimen in MDR-TB contacts with evidence of TB infection (TBI) can substantially reduce the risk of developing MDR-TB, and with no significant safety concerns (<xref ref-type="bibr" rid="B22">22</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>). The findings from two randomised-controlled trials of 6Lfx for MDR-TB contacts are expected in 2023 (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>The use of TPT in MDR-TB contacts requires an assessment of potential benefit versus risk, and benefit is greatest in contacts with infection (<xref ref-type="bibr" rid="B17">17</xref>). In 2019, tuberculin skin test (TST) was introduced in Daru to determine eligibility for 6Lfx as TPT for young child contacts of index cases with bacteriologically confirmed MDR-TB (without fluoroquinolone resistance) as part of a pilot project. This age group was selected as being high risk for disease due to care-giving relationships and high likelihood that exposure occurred in the household of the index case. A similar model of implementation was used as for 3RH for young child contacts of DS-TB, with the addition of TST. An operational research protocol with ethical approval was obtained and following informed consent, young child contacts with a positive TST and no evidence of disease were offered 6Lfx. To date, an effective model of care has been established with high uptake and completion.</p>
</sec>
<sec id="s2_3">
<title>Community engagement and patient education</title>
<p>Community engagement and education is critical to support contact screening and management, and especially to support TPT uptake and adherence given that this requires giving medication daily for months to a child or adolescent who is well. In Daru, several approaches are utilised to deliver education to people on treatment, their families and the wider community. An international community-based organisation has been providing TB health promotion and social mobilisation activities since 2011, focussing on enhancing detection and treatment support for active TB (<xref ref-type="bibr" rid="B6">6</xref>). A peer counselling model was introduced in 2017 involving People who have been Affected by, Living with or having Survived TB, known as PALS, who are trained and mentored to provide education and counselling support (<xref ref-type="bibr" rid="B11">11</xref>). The counselling program initially focused on support for people on treatment for active TB and expanded in 2018 to include families of children on TPT.</p>
<p>Locally tailored education materials including visual tools were developed, tested with community, and guides created for standard counselling sessions scheduled at key points of treatment. A child-friendly space with activities was initiated at the TPT follow-up clinic. Counselling and education are provided in the family&#x2019;s preferred language where possible. Due to the limited health literacy and linguistic diversity (&gt;3 languages) of the people South Fly District, visual tools and aides have been important. The term &#x201c;sleeping TB&#x201d; was used to explain the concepts of TBI. Community education and health promotion campaigns to increase understanding of &#x201c;sleeping TB&#x201d; and TPT were conducted including promotion from the town mayor and local leaders, public education sessions at churches, schools, sports events, community locations and local radio. The above measures have contributed to high rates of adherence and TPT completion.</p>
</sec>
<sec id="s2_4">
<title>Program monitoring and data systems</title>
<p>Monitoring and evaluation of contact screening and management programs are essential. However, comprehensive guidance does not exist regarding tools, data definitions or processes for programs to implement contextually adapted solutions. The WHO has defined minimum data and indicator definitions for TPT and the Zero TB Initiative has outlined a comprehensive set of indicators for the search-treat-prevent approach (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). The EMRS in Daru was adapted to include modules for contact screening and TPT in 2018.&#xa0;A household mapping tool that documents investigation of all close contacts of an index case is used as previously described (<xref ref-type="bibr" rid="B12">12</xref>). The public health team records patient data using paper-based records. A data entry team subsequently enters this data into the EMRS. Contact screening and management is monitored using a cascade-of-care framework for TB detection and prevention. The EMRS enables reporting of an individual-level cascade, rather than aggregate. Resources required to support the EMRS, including information technology expertise, programming skills and data entry capacity, are provided through partner support. Despite challenges, implementation has been successful, with the data system monitoring TPT uptake and outcome.</p>
</sec>
</sec>
<sec id="s3">
<title>Implementation challenges and considerations</title>
<p>Operational challenges include a chronic shortage of health care workers, interruption of CXR services, laboratory reagents and power and internet outages. The availability of international partner support has been critical to the TB program in Daru since 2011. Adopting a community-based model with mobile teams and task-shifting from medical and para-medical staff to nurses and community-health workers with training and technical support from partners has helped to address human resource issues. The COVID-19 pandemic has had a major impact on the delivery of TB services. From March 2020 until April 2022, contact screening was suspended initially due to public health restrictions and infection risks and subsequently health workforce shortages. Programmatic focus over this period was active TB treatment and care with case-finding limited to facility-based only (passive). Household contact screening and management restarted in April 2022.</p>
<p>Daru, and South Fly District have significant particular challenges in the social determinants of health which contribute to increased risk of TB transmission, with one of the highest measures of household poverty in the region, low levels of health literacy overcrowding food insecurity and low access to health services due to service availability, remoteness and lack of trust (<xref ref-type="bibr" rid="B7">7</xref>) (<xref ref-type="bibr" rid="B8">8</xref>). The TB program has had a concerted focus on community engagement, health promotion and patient-centred services. A major challenge has been identifying and reaching households which has been successfully addressed through the engagement of community leaders, household heads and community education. This patient and family-centred approach has built trust. Timely referrals for eligible TPT candidates for pre-initiation counselling also reduced delays in time to initiation of TPT. In the early implementation of TPT for young children, adherence issues were noted prompting an exploration and development of solutions for contributing issues through counsellors.</p>
<p>A Community Advisory Group, self-named TB Nanito Kopia Kodu (the Voice to Kill TB Forever) was formed from community consultations in late 2019 with members representing key stakeholder groups (e.g. churches, schools, businesses, key populations). The group&#x2019;s primary focus is providing community input and co-design for TB public health activities, including the development of community education materials and models to reach key populations such as adolescents and students, working adults (not present at home), prisoners, people with disabilities and the elderly. Accordingly, a comprehensive community education campaign has been developed with a participatory approach involving training of representatives from key populations.</p>
<p>Re-identification of individuals during multiple episodes across the screening and prevention cascades of care has been a particular challenge due to poor civil registration coverage (<xref ref-type="bibr" rid="B31">31</xref>). In PNG, people may give different names, age and residence from visit to visit with addresses not specific enough. Paper-based recording at multiple points of care also contributes to the problem by making it difficult to check a patient&#x2019;s details against existing information. The linkage of contacts to multiple index cases needs to be reconciled for reporting. This is currently addressed through local health worker and community knowledge of households and engagement <italic>via</italic> peer counsellors. Biometric systems have been proposed as a solution for patient identification, but cost, complexity and acceptability are barriers to implementing them. An immediate solution is patient-held records, such as health books or a card that can be issued and used to identify patients. However, these may get lost or not brought to patient visits. We have designed a potential solution for re-identification at low cost that supplements patient-held records with a memorisable unique identifier consisting of three common objects, represented with images. Even partial recall of this identifier can aid re-identification.</p>
<p>The primary challenge in Daru is the application of the household as the unit of intervention for contact screening and to deliver post-exposure management including detection of active TB and TPT. This is both from an implementation perspective and the fact that households may not be the optimal unit of intervention for timely detection of active TB and identifying those at risk of recent exposure for TPT (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). The socio-cultural context in Daru, as elsewhere in PNG, involves large multi-generational family structures based on kinship. However, there are some unique features with significant overcrowding in settlements and frequent travel between mainland villages and Daru Island, often for extended periods of time. This results in large &#x201c;households&#x201d; with complex family structures and population movement. Therefore, the operational household contact definition used is broad and includes those who have spent more than one night in the household.</p>
<p>Our experience in Daru is that most transmission is likely occurring outside the household, as noted even in children in other high-incidence settings (<xref ref-type="bibr" rid="B32">32</xref>). The likelihood of exposure and infection occurring outside of the household increases with age. Adolescence is a peak age for close and casual social contact and so in a highly endemic setting such as Daru, the majority of the population may be infected by adulthood (<xref ref-type="bibr" rid="B34">34</xref>). TST testing in MDR-TB household contacts in Daru has demonstrated a high prevalence of infection similar to reported elsewhere (<xref ref-type="bibr" rid="B35">35</xref>). The majority of TB and MDR-TBnotifications are in older adolescents and young adults, with around 70% of TB notified in those 15-34 years (<xref ref-type="bibr" rid="B5">5</xref>). Furthermore, with large household sizes and a very mobile population, an individual can be exposed to multiple index cases concurrently, including DS and MDR-TB. Therefore, consideration of alternative approaches in Daru to household contact management are warranted.</p>
</sec>
<sec id="s4">
<title>Future directions &#x2013; moving beyond household contact screening and management</title>
<p>Until recently in high TB transmission settings, recommendations for TPT have been limited to specific high-risk groups for disease such as young child contacts and people living with HIV (<xref ref-type="bibr" rid="B16">16</xref>). Whilst important in reducing tuberculosis-related morbidity and mortality in these groups, the impact of TPT on community transmission by preventing new cases is small, likely negligible for young child contacts (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Therefore, a community-wide strategy has been considered in the design of an enhanced public health intervention and model of care that aims to increase TB detection and treatment while providing TPT to a broader population to reduce transmission in addition to TB morbidity and mortality (<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>). <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref> outlines our considerations for a comprehensive detect-treat-prevent strategy in a high TB transmission setting by age.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Considerations for a comprehensive detect-treat-prevent strategy in a high MDR-TB transmission setting by age. mWRD, molecular WHO-recommended rapid diagnostics; DS-TB, drug-susceptible tuberculosis; MDR/RR, multidrug-resistant/rifampicin-resistant tuberculosis; RH, rifampicin and isoniazid; Lfx, levofloxacin; CXR, chest. NB. Different considerations apply in high HIV transmission settings and special populations.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fitd-03-1085401-g001.tif"/>
</fig>
<p>First, programmatic scaling-up of contact screening and management that includes older children, adolescents and young adults in the community is planned. The 2020 WHO recommendations include a wider age range of TPT options for HIV-uninfected contacts (<xref ref-type="bibr" rid="B16">16</xref>). We therefore propose community-wide TST testing for Daru residents aged 5-34 years irrespective of household contact, with TPT provided to those with infection and no evidence of active TB, as part of a comprehensive approach to complement active case-finding. The model of community engagement and implementation described above will be applied and the household will be the unit of intervention. The application of a community-wide systematic screening for case detection aligns with recent WHO recommendations for settings with a TB prevalence of 0.5% such as Daru, and is based on new evidence of public health benefit (<xref ref-type="bibr" rid="B39">39</xref>). The decision to provide TPT for 5-34 years with infection is based on the following considerations: high-risk age group for active TB; high risk age group for transmission in the community; and lower risk of isoniazid-related toxicity due to TPT compared 35 years and older.</p>
<p>Second, in high transmission MDR-TB settings, consideration of a TPT regimen for older children, adolescents and adults that considers the possibility of infection with an MDR-TB strain irrespective of the index case is needed. A novel option is a combination TPT regimen of 6 months of daily isoniazid and levofloxacin (6HLfx) for 5&#x2013;34 year-olds with evidence of infection and no active TB. This TPT regimen is chosen to effectively treat infection with either DS or MDR-TB as a positive TST cannot determine drug susceptibility. Whilst exposure to both is common, the majority (&gt;80%) of TB in Daru is DS-TB. Isoniazid or rifampicin may not effectively treat infection with an MDR-TB strain. While it is plausible that levofloxacin alone may cover treatment of DS in addition to MDR infection, there is no definitive evidence of efficacy at present. There is circumstantial evidence that isoniazid may also be effective in the treatment of MDR infection (<xref ref-type="bibr" rid="B20">20</xref>). Rifapentine is currently not available in PNG and a three-drug regimen may have additional adverse effects over two. Therefore, isoniazid is included in the proposed regimen. Young child (&lt;5 years) contacts can be managed as per the strain of the index case. The optimal approach for management of fluoroquinolone-resistant TB infection is uncertain and should be individualised.</p>
<p>Third, it is critical to exclude active disease especially in adolescents and adults. An optimal age-related contact management algorithm is required to mitigate the risk &#x2013; individual and public health &#x2013; of generating resistance including to fluoroquinolones. This risk needs to be negligible, similar to isoniazid and rifampicin (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>). In addition to symptom screening, the inclusion of CXR and sputum Xpert Ultra in the algorithm will provide high sensitivity for detection. The optimal age-related use of chest-radiography in asymptomatic, HIV-uninfected people aged 5&#x2013;34 years to rule out active TB before TPT is unclear. WHO guidelines recommend that asymptomatic young child contacts or PLHIV do not require CXR before TPT initiation. It is likely that the same approach could be applied to all well children (&lt;10 years) with infection without risk of not detecting sub-clinical disease. This is the approach that is being considered in Daru. In addition to a negative symptom screen, CXR will be routinely included in screening adolescents and adults (&#x2265;10 years), as it is important to exclude active TB with a sensitive algorithm prior to TPT initiation. Computer-aided detection of CXR is recommended for TB screening in people &#x2265;15 and this will also be used for screening young adolescents (10-14 years). This is because adolescents with TB commonly present with adult-type disease such as with cavitation, most critical to rule-out before initiating TPT.</p>
<p>The significant health individual and health system burden of ongoing MDR-TB transmission is a compelling argument for the potential benefit of the community-wide approach to detect, treat and prevent DS and MDR-TB and likely outweighs potential individual treatment risks with 6HLfx (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B42">42</xref>). Operational mixed-methods research will evaluate the impact, acceptability, feasibility and cost-effectiveness. The intervention will build on the local leadership, programmatic experience and platform of innovation that has been established in Daru. Ongoing engagement and placing&#xa0;the affected community at the centre of the response remains critical to success and towards ending tuberculosis in high-transmission settings.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>SM, SG and GKH contributed to conception and design of the study. GD, SB, TK, GC, SF, AM, JG, CM, TM, SU, SG and SM developed sections of the manuscript. SM wrote the first draft of the manuscript. All authors contributed to manuscript revision and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>The Reducing the Impact of Drug-resistant TB (RID-TB) project is supported by the Australian Government and implemented by the Burnet Institute as part of the Western Province TB Program in partnership with the Western Provincial Health Authority, PNG Australia Transition to Health (PATH) and World Vision International. The Stronger Systems for Drug-resistant Tuberculosis and Malaria (STRATUM) GNT 1152867 project was supported by the Australian Government and implemented by the Menzies School of Health Research and the Burnet Institute. The Comprehensive community-based solutions to reduce TB in high-burden MDR-TB settings (CURB-TB) project received grant funding from the Australian Government (GNT1201008) SM is a recipient of an NHMRC Postgraduate Scholarship (GNT 1191614) and the RACP NHMRC Woolcock Scholarship.</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organisation</collab>
</person-group>. <source>Global tuberculosis report 2022</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organisation</publisher-name> (<year>2022</year>). Available at: <uri xlink:href="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022">https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022</uri>.</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aia</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wangchuk</surname> <given-names>L</given-names>
</name>
<name>
<surname>Morishita</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kisomb</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yasi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kal</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Epidemiology of tuberculosis in Papua new Guinea: analysis of case notification and treatment-outcome data, 2008&#x2013;2016</article-title>. <source>West Pac Surveill Response J</source> (<year>2018</year>) <volume>9</volume>:<fpage>9</fpage>&#x2013;<lpage>19</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.5365/wpsar.2018.9.1.006</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aia</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kal</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lavu</surname> <given-names>E</given-names>
</name>
<name>
<surname>John</surname> <given-names>LN</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Coulter</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The burden of drug-resistant tuberculosis in Papua new Guinea: Results of a Large population-based survey</article-title>. <source>PloS One</source> (<year>2016</year>) <volume>11</volume>:<elocation-id>e0149806</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0149806</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kase</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dakulala</surname> <given-names>P</given-names>
</name>
<name>
<surname>Bieb</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Outbreak of multidrug-resistant tuberculosis on daru island: an update</article-title>. <source>Lancet Respir</source> (<year>2016</year>) <volume>4</volume>(<issue>8</issue>):<fpage>e40</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s2213-2600(16)30094-7</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hiasihri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>G</given-names>
</name>
<name>
<surname>Honjepari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tugo</surname> <given-names>O</given-names>
</name>
<name>
<surname>Taune</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The emergency response to multidrug-resistant tuberculosis in daru, Western province, Papua new Guinea, 2014&#x2013;2017</article-title>. <source>Public Health Action</source> (<year>2019</year>) <volume>9</volume>:<fpage>S4</fpage>&#x2013;<lpage>S11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/pha.18.0074</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Specialist Health Service</collab>
</person-group>. <source>TB prevention and control in PNG. report of the review of contribution of DFAT investments 2011-2018</source> (<year>2019</year>). Available at: <uri xlink:href="https://www.dfat.gov.au/publications/aid/review-dfat-support-tb-response-papua-new-guinea-2011-2018-management-response">https://www.dfat.gov.au/publications/aid/review-dfat-support-tb-response-papua-new-guinea-2011-2018-management-response</uri>.</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Busilacchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Butler</surname> <given-names>J</given-names>
</name>
<name>
<surname>Putten</surname> <given-names>IV</given-names>
</name>
<name>
<surname>Maru</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Posu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Asymmetrical development across transboundary regions: The case of the Torres strait treaty region (Australia and Papua new Guinea)</article-title>. <source>Sustainability</source> (<year>2018</year>) <volume>10</volume>:<page-range>4200&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/su10114200</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jops</surname> <given-names>P</given-names>
</name>
<name>
<surname>Kupul</surname> <given-names>M</given-names>
</name>
<name>
<surname>Trumb</surname> <given-names>RN</given-names>
</name>
<name>
<surname>Cowan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Exploring tuberculosis riskscapes in a Papua new guinean &#x2018;Hotspot.&#x2019;</article-title>. <source>Qual Health Res</source> (<year>2022</year>) <volume>32</volume>(<issue>11</issue>):<fpage>1747-62</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/10497323221111912</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taune</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ustero</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hiashiri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Aia</surname> <given-names>P</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Successful implementation of bedaquiline for multidrug-resistant TB treatment in remote Papua new Guinea</article-title>. <source>Public Health Action</source> (<year>2019</year>) <volume>9</volume>:<page-range>S73&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/pha.18.0071</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>GKL</given-names>
</name>
<name>
<surname>Pawape</surname> <given-names>G</given-names>
</name>
<name>
<surname>Taune</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hiasihri</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ustero</surname> <given-names>P</given-names>
</name>
<name>
<surname>O&#x2019;Brien</surname> <given-names>DP</given-names>
</name>
<etal/>
</person-group>. <article-title>Telemedicine in resource-limited settings to optimize care for multidrug-resistant tuberculosis</article-title>. <source>Front Public Health</source> (<year>2019</year>) <volume>7</volume>:<elocation-id>222</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fpubh.2019.00222</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adepoyibi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Keam</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kuma</surname> <given-names>A</given-names>
</name>
<name>
<surname>Haihuie</surname> <given-names>T</given-names>
</name>
<name>
<surname>Hapolo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>A pilot model of patient education and counselling for drug-resistant tuberculosis in daru, Papua new Guinea</article-title>. <source>Public Health Action</source> (<year>2019</year>) <volume>9</volume>:<page-range>S80&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/pha.18.0096</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Honjepari</surname> <given-names>A</given-names>
</name>
<name>
<surname>Madiowi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Madjus</surname> <given-names>S</given-names>
</name>
<name>
<surname>Burkot</surname> <given-names>C</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Implementation of screening and management of household contacts of tuberculosis cases in daru, Papua new Guinea</article-title>. <source>Public Health Action</source> (<year>2019</year>) <volume>9</volume>:<page-range>S25&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/pha.18.0072</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kendall</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Sahu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Fox</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Varaine</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cox</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>What will it take to eliminate drug-resistant tuberculosis</article-title>? <source>Int J Tuberc Lung Dis</source> (<year>2019</year>) <volume>23</volume>:<page-range>535&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/ijtld.18.0217</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organisation</collab>
</person-group>. <source>Consolidated guidelines on tuberculosis. module 3: diagnosis - rapid diagnostics for tuberculosis detection, 2021 update</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organsation</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/9789240029415">https://www.who.int/publications/i/item/9789240029415</uri>.</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Rutherford</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Audas</surname> <given-names>R</given-names>
</name>
<name>
<surname>van</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>SM</given-names>
</name>
</person-group>. <article-title>Closing the policy-practice gap in the management of child contacts of tuberculosis cases in developing countries</article-title>. <source>PloS Med</source> (<year>2011</year>) <volume>8</volume>:<elocation-id>e1001105</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pmed.1001105.t003</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organisation</collab>
<collab>World Health Organisation</collab>
</person-group>. <source>WHO consolidated guidelines on tuberculosis: module 1 preventative treatment</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organisation</publisher-name> (<year>2020</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/9789240001503">https://www.who.int/publications/i/item/9789240001503</uri>.</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cords</surname> <given-names>O</given-names>
</name>
<name>
<surname>Horsburgh</surname> <given-names>CR</given-names>
</name>
<name>
<surname>Andrews</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Consortium</surname> <given-names>PTCS</given-names>
</name>
<name>
<surname>Acuna-Villaorduna</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis</article-title>. <source>Lancet</source> (<year>2020</year>) <volume>395</volume>:<page-range>973&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0140-6736(20)30166-5</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwoebel</surname> <given-names>V</given-names>
</name>
<name>
<surname>Koura</surname> <given-names>KG</given-names>
</name>
<name>
<surname>Adjobimey</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gnanou</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wandji</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Gody</surname> <given-names>J-C</given-names>
</name>
<etal/>
</person-group>. <article-title>Tuberculosis contact investigation and short-course preventive therapy among young children in Africa</article-title>. <source>Int J Tuberc Lung Dis</source> (<year>2020</year>) <volume>24</volume>:<page-range>452&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/ijtld.19.0712</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apis</surname> <given-names>V</given-names>
</name>
<name>
<surname>Landi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Islam</surname> <given-names>T</given-names>
</name>
<name>
<surname>Amini</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sabumi</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Outcomes in children treated for tuberculosis with the new dispersible fixed-dose combinations in port Moresby</article-title>. <source>Public Heal Action</source> (<year>2019</year>) <volume>9</volume>:<page-range>S32&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/pha.18.0062</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>C-C</given-names>
</name>
<name>
<surname>Becerra</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Calderon</surname> <given-names>R</given-names>
</name>
<name>
<surname>Contreras</surname> <given-names>C</given-names>
</name>
<name>
<surname>Galea</surname> <given-names>J</given-names>
</name>
<name>
<surname>Grandjean</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Isoniazid preventive therapy in contacts of multidrug-resistant tuberculosis</article-title>. <source>Am J Resp Crit Care</source> (<year>2020</year>) <volume>202</volume>:<page-range>1159&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1164/rccm.201908-1576oc</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Demers</surname> <given-names>A-M</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>S</given-names>
</name>
<name>
<surname>McCallum</surname> <given-names>S</given-names>
</name>
<name>
<surname>Eisenach</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hughes</surname> <given-names>M</given-names>
</name>
<name>
<surname>Naini</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Drug susceptibility patterns of mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial</article-title>. <source>BMC Infect Dis</source> (<year>2021</year>) <volume>21</volume>:<fpage>205</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12879-021-05884-4</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byrne</surname> <given-names>AL</given-names>
</name>
<name>
<surname>Fox</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Marais</surname> <given-names>BJ</given-names>
</name>
</person-group>. <article-title>Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis</article-title>. <source>Future Microbiol</source> (<year>2018</year>) <volume>13</volume>:<page-range>577&#x2013;88</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2217/fmb-2017-0236</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname> <given-names>AA</given-names>
</name>
<name>
<surname>Gandhi</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Lash</surname> <given-names>TL</given-names>
</name>
<name>
<surname>Cranmer</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Omer</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Ahmed</surname> <given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Effectiveness of preventive therapy for persons exposed at home to drug-resistant tuberculosis, Karachi, Pakistan</article-title>. <source>Emerg Infect Dis</source> (<year>2021</year>) <volume>27</volume>:<page-range>805&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3201/eid2703.203916</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Seddon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fred</surname> <given-names>D</given-names>
</name>
<name>
<surname>Amanullah</surname> <given-names>F</given-names>
</name>
<name>
<surname>Schaaf</surname> <given-names>H</given-names>
</name>
<name>
<surname>Starke</surname> <given-names>J</given-names>
</name>
<name>
<surname>Keshavjee</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <source>Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. policy brief no. 1</source>. <publisher-loc>Dubai, United Arab Emirates</publisher-loc>: <publisher-name>Harvard Medical School Center for Global Health Delivery, Dubai</publisher-name> (<year>2015</year>). Available at: <uri xlink:href="https://www.zerotbinitiative.org/resources-for-coalitions">https://www.zerotbinitiative.org/resources-for-coalitions</uri>.</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seddon</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Hesseling</surname> <given-names>AC</given-names>
</name>
<name>
<surname>Finlayson</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fielding</surname> <given-names>K</given-names>
</name>
<name>
<surname>Cox</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hughes</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Preventive therapy for child contacts of multidrug-resistant tuberculosis: A prospective cohort study</article-title>. <source>Clin Infect Dis</source> (<year>2013</year>) <volume>57</volume>:<page-range>1676&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cid/cit655</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bamrah</surname> <given-names>S</given-names>
</name>
<name>
<surname>Brostrom</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dorina</surname> <given-names>F</given-names>
</name>
<name>
<surname>Setik</surname> <given-names>L</given-names>
</name>
<name>
<surname>Song</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kawamura</surname> <given-names>LM</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment for LTBI in contacts of MDR-TB patients, federated states of Micronesia, 2009-2012</article-title>. <source>Int J Tuberc Lung Dis</source> (<year>2014</year>) <volume>18</volume>:<page-range>912&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/ijtld.13.0028</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seddon</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Garcia-Prats</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Purchase</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Osman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Demers</surname> <given-names>A-M</given-names>
</name>
<name>
<surname>Hoddinott</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)</article-title>. <source>Trials</source> (<year>2018</year>) <volume>19</volume>:<fpage>693</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13063-018-3070-0</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fox</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>T-A</given-names>
</name>
<name>
<surname>Tran</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Marais</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial</article-title>. <source>BMJ Open</source> (<year>2020</year>) <volume>10</volume>:<elocation-id>e033945-8</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/bmjopen-2019-033945</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>World Health Organisation</collab>
</person-group>. <source>WHO operational handbook on tuberculosis module 2: Screening &#x2013; systematic screening for tuberculosis disease</source> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/9789240022614">https://www.who.int/publications/i/item/9789240022614</uri>.</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="web">
<person-group person-group-type="author">
<collab>Zero TB Initiative</collab>
</person-group>. <source>A best-practice framework of program indicators for monitoring a comprehensive approach to the tuberculosis epidemic</source> (<year>2017</year>). Available at: <uri xlink:href="https://www.zerotbinitiative.org/resources-for-coalitions">https://www.zerotbinitiative.org/resources-for-coalitions</uri>.</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>Pacific Community (SPC)</collab>
</person-group>. <source>Papua New Guinea civil registration and vital statistics action plan (2020-2021)</source>. <publisher-loc>Noumea, New Caledonia</publisher-loc>: <publisher-name>The Pacific Community (SPC)</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://sdd.spc.int/digital_library/papua-new-guinea-civil-registration-and-vital-statistics-action-plan-2020-2021">https://sdd.spc.int/digital_library/papua-new-guinea-civil-registration-and-vital-statistics-action-plan-2020-2021</uri>.</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>NC</given-names>
</name>
<name>
<surname>Cords</surname> <given-names>O</given-names>
</name>
<name>
<surname>Hill</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Khan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hatherill</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Paediatric tuberculosis transmission outside the household: challenging historical paradigms to inform future public health strategies</article-title>. <source>Lancet Respir Med</source> (<year>2019</year>) <volume>7</volume>:<page-range>544&#x2013;52</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s2213-2600(19)30137-7</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCreesh</surname> <given-names>N</given-names>
</name>
<name>
<surname>White</surname> <given-names>RG</given-names>
</name>
</person-group>. <article-title>An explanation for the low proportion of tuberculosis that results from transmission between household and known social contacts</article-title>. <source>Sci Rep-uk</source> (<year>2018</year>) <volume>8</volume>:<fpage>5382</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-018-23797-2</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCreesh</surname> <given-names>N</given-names>
</name>
<name>
<surname>Morrow</surname> <given-names>C</given-names>
</name>
<name>
<surname>Middelkoop</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wood</surname> <given-names>R</given-names>
</name>
<name>
<surname>White</surname> <given-names>RG</given-names>
</name>
</person-group>. <article-title>Estimating age-mixing patterns relevant for the transmission of airborne infections</article-title>. <source>Epidemics-neth</source> (<year>2019</year>) <volume>28</volume>:<fpage>100339</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.epidem.2019.03.005</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname> <given-names>NS</given-names>
</name>
<name>
<surname>Yuen</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Heo</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tolman</surname> <given-names>AW</given-names>
</name>
<name>
<surname>Becerra</surname> <given-names>MC</given-names>
</name>
</person-group>. <article-title>Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis</article-title>. <source>Clin Infect Dis</source> (<year>2014</year>) <volume>58</volume>:<page-range>381&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cid/cit643</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>L</given-names>
</name>
<name>
<surname>Theron</surname> <given-names>G</given-names>
</name>
<name>
<surname>Wood</surname> <given-names>R</given-names>
</name>
<name>
<surname>Marais</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Mycobacterium tuberculosis transmission in high-incidence settings&#x2013;new paradigms and insights</article-title>. <source>Pathogens</source> (<year>2022</year>) <volume>11</volume>:<elocation-id>1228</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pathogens11111228</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rangaka</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cavalcante</surname> <given-names>S</given-names>
</name>
<name>
<surname>Marais</surname> <given-names>BJ</given-names>
</name>
<name>
<surname>Thim</surname> <given-names>S</given-names>
</name>
<name>
<surname>Martinson</surname> <given-names>N</given-names>
</name>
<name>
<surname>Swaminathan</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection</article-title>. <source>Lancet</source> (<year>2015</year>) <volume>386</volume>(<issue>10010</issue>):<fpage>2344-53</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0140-6736(15)00323-2</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comstock</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ferebee</surname> <given-names>S</given-names>
</name>
<name>
<surname>Hammes</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>A controlled trial of community-wide isoniazid prophylaxis in Alaska</article-title>. <source>Am Rev Respir Dis</source> (<year>1967</year>) <volume>95</volume>(<issue>6</issue>):<fpage>935-43</fpage>. doi:&#xa0;doi: <pub-id pub-id-type="doi">10.1164/arrd.1967.95.6.935</pub-id>.
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="book">
<person-group person-group-type="author">
<collab>World Health Organisation</collab>
</person-group>. <source>WHO consolidated guidelines on tuberculosis module 2: Screening &#x2013; systematic screening for tuberculosis disease</source>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organisation</publisher-name> (<year>2021</year>). Available at: <uri xlink:href="https://www.who.int/publications/i/item/9789240022676">https://www.who.int/publications/i/item/9789240022676</uri>. doi:&#xa0;<pub-id pub-id-type="doi">10.30978/tb2021-2-86</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balcells</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Thomas</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Godfrey-Faussett</surname> <given-names>P</given-names>
</name>
<name>
<surname>Grant</surname> <given-names>AD</given-names>
</name>
</person-group>. <article-title>Isoniazid preventive therapy and risk for resistant tuberculosis</article-title>. <source>Emerg Infect Dis</source> (<year>2006</year>) <volume>12</volume>:<page-range>744&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3201/eid1205.050681</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>den Boon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Matteelli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Getahun</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis</article-title>. <source>Int J Tuberc Lung Dis</source> (<year>2016</year>) <volume>20</volume>:<page-range>1065&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5588/ijtld.15.0908</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marks</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Mase</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Morris</surname> <given-names>SB</given-names>
</name>
</person-group>. <article-title>Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis</article-title>. <source>Clin Infect Dis</source> (<year>2017</year>) <volume>64</volume>:<page-range>1670&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/cid/cix208</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>
